| Editor's Note: Throughout history, the biotech sector has proven to provide big potential returns for investors. That's why in today's guest article, Oxford Club Chief Investment Strategist Alexander Green is showing how a new development in artificial intelligence could be huge for a certain biotech company. He's also been tracking insider buying on this under-the-radar biotech group, and now he's ready to share his next big insider opportunity with you. Click here to see details on Alex's top insider stock pick right now... completely free of charge. - Ryan Fitzwater, Publisher
Alexander Green, Chief Investment Strategist, The Oxford Club Over the past decade, investing in biotech stocks with insider buying has tripled the S&P 500's return. Tandem Diabetes Care (Nasdaq: TNDM) and Exscientia PLC (Nasdaq: EXAI) are prime examples of some I've recommended. The former was a particularly big winner, allowing my readers to lock in up to a 1,795% gain in less than one year. Needless to say, I'm bullish on the industry. But there's one big problem faced by most biotechs: Drug discovery. More specifically, how long drug discovery takes and how much it costs. Drug discovery hasn't changed much in the last century. It still takes up to a decade or even more in some cases to develop a new drug. It's a long, manual process with lots of trial and error (not to mention government red tape) that can be performed only by highly trained resources. Because of that, it's also astronomically expensive. The average cost to develop a new drug is $2.6 billion... That's a lot of money to shell out for a drug that may not even make the cut - a full 9 out of 10 drugs entering Phase 1 clinical trials never make it to market. They get shot down by the Food and Drug Administration (FDA), often for good reason. But by that point, it's already cost billions of dollars to develop them. That's changing, though. And it's changing fast. Artificial intelligence (AI) can make drug development a faster and cheaper process with fewer costly failures. It can shorten drug development times from a decade-plus on average to just a few short years and give us better, longer, healthier lives in the process. And there's one company that's using AI to support the entire biotech industry. Because, unlike many biotech companies that focus on only one specific segment of the drug development process, this company helps other biotechs make new breakout discoveries. In fact, it has supported 80% of all FDA-approved novel drugs that have hit the market over the past five years. If you're taking a new drug, there's a good chance this company helped develop it. I'm expecting big things for this company because its insiders are piling in at a breakneck pace... | 
No comments:
Post a Comment